What happened
Shares of Doximity (NYSE: DOCS) leaped 24% on Wednesday after the networking platform for medical professionals announced strong third-quarter growth metrics.
So what
Doximity's revenue surged 67% year over year to $97.9 million in its fiscal 2022 third quarter, which ended on Dec. 31.
Pharmaceutical companies and other healthcare providers are ramping up their advertising spend on Doximity's network. "We had a strong Q3 led by our existing clients as our net revenue retention rate hit 171%," CEO Jeff Tangney said in a press release. Essentially, that means Doximity's customers spent 71% more than they did in the prior-year period.
Image source: Getty Images.
Doximity is benefiting from the advertising-industry's migration from TV and other traditional formats to easier-to-track -- and often more effective -- online channels. Doximity's profits, in turn, are soaring.
Its net income rocketed 223% to $55.6 million, or $0.26 per share. On an adjusted basis, its earnings before interest, taxes, depreciation, and amortization (EBITDA) increased 119%, to $47 million.
Now what
These results prompted Doximity to boost its full-year sales and earnings forecast. Management now expects revenue and adjusted EBITDA of $338.9 million to $339.9 million and $144.9 million to $145.9 million, respectively, in fiscal 2022. It also sees revenue growing an additional 33%, to $450 million, in fiscal 2023.
Additionally, Doximity said it struck a deal to acquire Amion, a leading on-call physician-scheduling site. Nearly 200,000 doctors use Amion's tools to manage their day-to-day schedules.
The deal values Amion at $82.5 million, including $53.5 million in cash and up to $29 million in earn-out payments. The transaction is expected to close in April.
10 stocks we like better than Doximity, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Doximity, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of January 20, 2022
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool owns and recommends Doximity, Inc. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
